Activity Number and Title
24HT00086 Understanding Hemophilia
Release Date
July 15, 2024
Expiration Date
5:00 PM Eastern, July 15, 2026
The estimated time to complete this activity is 120 minutes.
Purpose Statement
"Understanding Hemophilia" is a 6-part online learning activity that aims to enable clinicians at U.S. Hemophilia Treatment Centers to gain knowledge and develop expertise on the pathogenesis, inheritance, symptoms, potential complications, and clinical management of hemophilia.
Activity Description
This 6-part online learning activity introduces basic concepts of hemophilia.
Part 1: Pathogenesis & Inheritance examines the coagulation system and processes, the deficit in hemophilia that interferes with clot formation, differences among types of hemophilia, and the sex-linked inheritance pattern of hemophilia.
Part 2: Symptoms & Sequelae distinguishes bleeding patterns and clinical presentation of hemophilia based on severity, differentiates types of bleeding episodes, and discusses physical/psychosocial sequelae of hemophilia.
Part 3: Factor Concentrates & Hemophilia Management discusses episodic and prophylactic management of hemophilia with clotting factor concentrate, different factor therapy protocols, and nursing considerations in administration of clotting factor concentrates.
Part 4: Introduction to Inhibitors explains the immune response and inhibitor development, signs/symptoms and risk factors of inhibitors, the impact of inhibitors on persons with hemophilia, inhibitor treatment strategies and challenges, and the positive health outcomes of immune tolerance induction therapy.
Part 5: Non-Factor Therapies covers gene therapy for hemophilia and the novel agent emicizumab. Gene therapy includes goals of therapy, delivery of gene therapy, eligibility criteria, patient readiness considerations pre- and post-therapy, and long-term follow-up post-therapy.
Part 6: Carrier Considerations reviews hemophilia sex-linked genetics and introduces recommendations for the management of carriers and women with hemophilia, neonatal diagnosis and circumcision in males with hemophilia, and key considerations of postpartum management of carriers and women with hemophilia.
Target Audience
This accredited continuing education activity is designed for physical therapists, nurses, nurse practitioners, social workers and other clinical and non-clinical staff at federally recognized U.S. Hemophilia Treatment Centers who wish to develop an understanding of basic concepts of hemophilia. This activity is particularly appropriate for clinicians within their first six months of employment at an HTC.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Describe the pathogenesis and inheritance patterns concerning the different factor deficiencies in hemophilia including the symptoms and sequelae that may occur
- Discuss the target factor levels for situational bleeding episodes in conjunction with the appropriate factor replacement protocols, prophylactic treatments, and nursing considerations in administration of clotting factor concentrates
- Review the development and impact of inhibitors on persons with hemophilia, including signs and symptoms, risk factors, treatment implications, and nursing considerations
- Describe the goals of hemophilia gene therapy and describe the mechanism of action for hemophilia gene therapy
- Summarize the MASAC recommendations on the use of Emicizumab such as the indications, management approaches, and concurrent use with bypassing agents
- Articulate the role of genetic testing in the identification of potential carriers and women with hemophilia and the hemostatic management recommendations during pregnancy, labor and delivery, and the postpartum phases
Faculty
- Jennifer Maahs, MSN, PNP
- Amy Shapiro, MD
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity.
- Complete the evaluation.
- Complete the post-test with a score of 80% or better.
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accredited Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 2.0 ANCC contact hour(s). This activity is provided for 0.3 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.
SOCIAL WORKERS
As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 2 clinical continuing education credits. The content level of this activity is beginner.
PHYSICAL THERAPISTS
This activity is approved for physical therapy continuing education units (CEUs) through the California Physical Therapy Association (CPTA) (Approved for 0.2 CEUs by CPTA #24-215) from May 24, 2024 to May 24, 2025. While many states recognize continuing education credits from CPTA, please verify with your state Board that these credits are acceptable in your state. To learn more about CPTA, visit https://www.ccapta.org.
Financial Support
Partners in Bleeding Disorders Education Programs are currently supported by educational grants from Genentech, a member of the Roche Group; Takeda Pharmaceuticals U.S.A., Inc.; and Novo Nordisk.
Contact Information
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser